Chinese expert consensus on antithrombotic management of high-risk elderly patients with chronic coronary syndrome

被引:2
作者
Zhang, Cuntai [1 ]
Wang, Xiaoming [2 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Geriatr, Wuhan 430030, Peoples R China
[2] Air Force Med Univ, Xijing Hosp, Dept Geriatr, Xian 710032, Peoples R China
关键词
antithrombotic drugs; chronic coronary syndrome; coronary artery disease; DUAL ANTIPLATELET THERAPY; ATRIAL-FIBRILLATION; ARTERY-DISEASE; VENOUS THROMBOEMBOLISM; DOUBLE-BLIND; ORAL ANTICOAGULATION; EUROPEAN-SOCIETY; DECISION PATHWAY; ISCHEMIC-STROKE; POSITION PAPER;
D O I
10.1002/agm2.12234
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
The prevalence and mortality of coronary artery disease (CAD) in China are still at an increasing stage. CAD can be classified as acute coronary syndrome (ACS) or chronic coronary syndrome (CCS). CCS is the main manifestation type of elderly patients with CAD, with a large number of patients, long course of disease, and poor prognosis, leading to decreased quality of life and heavy disease burden and economic burden. Especially in patients with high-risk CCS, the case fatality rate and total mortality are high. In order to better standardize the antithrombotic treatment of elderly patients with high-risk CCS, the Geriatrics Branch of the Chinese Medical Association organizes domestic experts to develop this consensus for clinicians' reference based on published clinical research evidence, combined with relevant guidelines, consensus, and expert recommendations in China and abroad. Antithrombotic principles in patients with CCS: (1) Ischemic and bleeding risks should be adequately assessed to determine treatment strategies before initiating antithrombotic therapy. (2) Dual antiplatelet therapy (DAPT) or dual pathway inhibition (DPI) is recommended for patients with high ischemia risk and without high bleeding risk. (3) For CCS patients with low thrombotic risk and/or excessive bleeding risk, intensive antithrombotic therapy is suggested to avoid.image
引用
收藏
页码:4 / 24
页数:21
相关论文
共 99 条
  • [1] Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy
    Agewall, Stefan
    Cattaneo, M.
    Collet, J. P.
    Andreotti, F.
    Lip, G. Y. H.
    Verheugt, F. W. A.
    Huber, K.
    Grove, E. L.
    Morais, J.
    Husted, S.
    Wassmann, S.
    Rosano, G.
    Atar, D.
    Pathak, A.
    Kjeldsen, K.
    Storey, R. F.
    [J]. EUROPEAN HEART JOURNAL, 2013, 34 (23) : 1708 - +
  • [2] Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial
    Alexander, Karen P.
    Brouwer, Marc A.
    Mulder, Hillary
    Vinereanu, Dragos
    Lopes, Renato D.
    Proietti, Marco
    Al-Khatib, Sana M.
    Hijazi, Ziad
    Halvorsen, Sigrun
    Hylek, Elaine M.
    Verheugt, Freek W. A.
    Alexander, John H.
    Wallentin, Lars
    Granger, Christopher B.
    [J]. AMERICAN HEART JOURNAL, 2019, 208 : 123 - 131
  • [3] Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
    Anand, Sonia S.
    Bosch, Jackie
    Eikelboom, John W.
    Connolly, Stuart J.
    Diaz, Rafael
    Widimsky, Peter
    Aboyans, Victor
    Alings, Marco
    Kakkar, Ajay K.
    Keltai, Katalin
    Maggioni, Aldo P.
    Lewis, Basil S.
    Stoerk, Stefan
    Zhu, Jun
    Lopez-Jaramillo, Patricio
    O'Donnell, Martin
    Commerford, Patrick J.
    Vinereanu, Dragos
    Pogosova, Nana
    Ryden, Lars
    Fox, Keith A. A.
    Bhatt, Deepak L.
    Misselwitz, Frank
    Varigos, John D.
    Vanassche, Thomas
    Avezum, Alvaro A.
    Chen, Edmond
    Branch, Kelley
    Leong, Darryl P.
    Bangdiwala, Shrikant I.
    Hart, Robert G.
    Yusuf, Salim
    [J]. LANCET, 2018, 391 (10117) : 219 - 229
  • [4] Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis
    Andreotti, Felicita
    Rocca, Bianca
    Husted, Steen
    Ajjan, Ramzi A.
    ten Berg, Jurrien
    Cattaneo, Marco
    Collet, Jean-Philippe
    De Caterina, Raffaele
    Fox, Keith A. A.
    Halvorsen, Sigrun
    Huber, Kurt
    Hylek, Elaine M.
    Lip, Gregory Y. H.
    Montalescot, Gilles
    Morais, Joao
    Patrono, Carlo
    Verheugt, Freek W. A.
    Wallentin, Lars
    Weiss, Thomas W.
    Storey, Robert F.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 (46) : 3238 - +
  • [5] Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED Bleeding Risk-Prediction Scores in Patients With Atrial Fibrillation Undergoing Anticoagulation
    Apostolakis, Stavros
    Lane, Deirdre A.
    Guo, Yutao
    Buller, Harry
    Lip, Gregory Y. H.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (09) : 861 - 867
  • [6] Atherosclerosis and Coronary Heart Disease Working Group of Chinese Society of Cardiology, 2021, Zhonghua Xin Xue Guan Bing Za Zhi, V49, P432, DOI 10.3760/cma.j.cn112148-20210125-00088
  • [7] Effects of Clopidogrel Added to Aspirin in Patients with Recent Lacunar Stroke
    Benavente, Oscar R.
    Hart, Robert G.
    McClure, Leslie A.
    Szychowski, Jeffrey M.
    Coffey, Christopher S.
    Pearce, Lesly A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (09) : 817 - 825
  • [8] Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial
    Bhatt, Deepak L.
    Flather, Marcus D.
    Hacke, Werner
    Berger, Peter B.
    Black, Henry R.
    Boden, William E.
    Cacoub, Patrice
    Cohen, Eric A.
    Creager, Mark A.
    Easton, J. Donald
    Hamm, Christian W.
    Hankey, Graeme J.
    Johnston, S. Claiborne
    Mak, Koon-Hou
    Mas, Jean-Louis
    Montalescot, Gilles
    Pearson, Thomas A.
    Steg, P. Gabriel
    Steinhubl, Steven R.
    Weber, Michael A.
    Fabry-Ribaudo, Liz
    Hu, Tingfei
    Topol, Eric J.
    Fox, A. A.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (19) : 1982 - 1988
  • [9] Clopidogrel with or without Omeprazole in Coronary Artery Disease.
    Bhatt, Deepak L.
    Cryer, Byron L.
    Contant, Charles F.
    Cohen, Marc
    Lanas, Angel
    Schnitzer, Thomas J.
    Shook, Thomas L.
    Lapuerta, Pablo
    Goldsmith, Mark A.
    Laine, Loren
    Scirica, Benjamin M.
    Murphy, Sabina A.
    Cannon, Christopher P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (20) : 1909 - 1917
  • [10] Rivaroxaban in Peripheral Artery Disease after Revascularization
    Bonaca, Marc P.
    Bauersachs, Rupert M.
    Anand, Sonia S.
    Debus, E. Sebastian
    Nehler, Mark R.
    Patel, Manesh R.
    Fanelli, Fabrizio
    Capell, Warren H.
    Diao, Lihong
    Jaeger, Nicole
    Hess, Connie N.
    Pap, Akos F.
    Kittelson, John M.
    Gudz, Ivan
    Matyas, Lajos
    Krievins, Dainis K.
    Diaz, Rafael
    Brodmann, Marianne
    Muehlhofer, Eva
    Haskell, Lloyd P.
    Berkowitz, Scott D.
    Hiatt, William R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (21) : 1994 - 2004